VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 30, 2007) - Med BioGene Inc. (TSX VENTURE:MBI), a biotechnology company developing genetic biomarkers to improve screening, diagnosis, prognosis and treatment decisions for patients suffering from cancer and cardiovascular disease, today announced that Dr. Nathan Yoganathan, MBI's founder, President and Chief Scientific Officer has transitioned to a senior advisory role as Chief Scientific Advisor. Dr. Bradley McLean, a senior scientist with MBI, was appointed Chief Scientific Officer.
